Skip to main content
Shedir Pharma Group logo

Shedir Pharma Group — Investor Relations & Filings

Ticker · SHE ISIN · IT0005379620 LEI · 81560092B300849E9017 XMIL Manufacturing
Open in API
Filings indexed 124 across all filing types
Latest filing 2019-10-15 Regulatory Filings
Country IT Italy
Listing XMIL SHE

About Shedir Pharma Group

https://www.shedirpharmagroup.com

Shedir Pharma Group specializes in the research, development, formulation, and commercialization of health and wellness products. The company's portfolio encompasses nutraceuticals, dermocosmetics, medical devices, and pharmaceuticals. A key focus is on innovation, resulting in the creation of unique and patented product formulations that cover approximately 15 therapeutic areas. The group operates through specialized subsidiaries that manage the entire product lifecycle, from initial research and intellectual property to marketing and distribution. Products are offered in various forms, such as capsules, tablets, powders, liquids, and gels, targeting professionals in the medical and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
Ottenimento 3 brevetti Italiani Peaflosin, Senydem e Peamotix
Regulatory Filings Classification · 95% confidence The document is a press release (COMUNICATO STAMPA) from Shedir Pharma Group S.p.A. announcing the 'Ottenimento 3 brevetti Italiani' (Obtainment of 3 Italian Patents). This announcement details intellectual property achievements (patents for Peaflosin®, Senydem®, and Peamotix®) and provides context on the market segments they relate to. This type of announcement, concerning specific corporate developments that are not standard periodic financial reports (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or specific corporate news. Since there is no specific category for 'Patent Grant Announcement,' and it is a formal communication to the market regarding a significant corporate asset/development, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory disclosure, or potentially 'Capital/Financing Update' (CAP) if patents were viewed as core assets being secured, but RNS is the more appropriate general disclosure bucket for non-standard news. Given the context of AIM-Italia and the structure as a formal 'Informazione Regolamentata', RNS is the most suitable general classification for this type of market-sensitive, non-financial report news.
2019-10-15 Italian
Comunicazione pubblicazione del nuovo statuto sociale
Report Publication Announcement Classification · 98% confidence The document is a formal communication from Shedir Pharma Group S.p.A. dated October 2, 2019. The subject ('Oggetto') is 'statuto sociale' (bylaws/articles of association), and the title is 'Comunicazione pubblicazione del nuovo statuto sociale' (Communication of the publication of the new articles of association). The text explicitly states that the new articles of association, updated following a capital increase, have been filed and are available on the company website in the 'Corporate Governance / Documentazione societaria' section. This structure—a brief announcement stating that a corporate document (the updated bylaws) has been published and is available elsewhere—fits the definition of a Report Publication Announcement (RPA). It is not the full governance report (CGR) itself, but the notice of its publication. Given the short length (4445 chars) and the explicit reference to publication, RPA is the most appropriate classification.
2019-10-02 Italian
Comunicazione variazione capitale sociale
Capital/Financing Update Classification · 98% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled "Comunicazione variazione capitale sociale" (Communication of share capital variation). It explicitly details the change in the total number of shares and the resulting new share capital amount following the partial execution of an over-allotment option (Greenshoe) related to a previous capital increase. This type of announcement, focusing on changes to the company's capital structure (share count, capital amount), directly corresponds to the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). While it relates to capital, it is a specific announcement of a change, fitting best under 'Capital/Financing Update' (CAP) rather than the general 'Share Issue/Capital Change' (SHA), which often covers new issuances or splits, although CAP is the most precise fit for post-IPO capital adjustments like Greenshoe execution.
2019-10-01 Italian
Approvata la Relazione Consolidata Semestrale 2019
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Shedir Pharma Group S.p.A. announcing the approval of their consolidated half-year financial report for the period ending June 30, 2019. It contains key financial highlights (Revenue, EBITDA, Net Income, Net Financial Position) and includes tables summarizing the financial performance. While it mentions that the full report is available on their website, the document itself provides substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than a mere publication announcement. H1 2019
2019-09-30 Italian
Ottenimento brevetto italiano Zexin
Legal Proceedings Report Classification · 99% confidence The document is a press release ('COMUNICATO STAMPA') from Shedir Pharma Group S.p.A. dated September 5, 2019, announcing the 'Ottenimento brevetto italiano Zexin' (Obtainment of Italian patent Zexin). It details the nature of the patent (a controlled release system) and its potential applications. This type of announcement, concerning intellectual property or specific operational updates that are not standard financial reports (10-K, IR, ER) or mandatory regulatory filings like insider trading (DIRS) or major shareholding changes (MRQ), fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the patent was contested, but since it's an announcement of an achievement, RNS is the most appropriate general regulatory announcement category, as it doesn't fit the specific definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Given the context of an Italian regulated information notice ('Informazione Regolamentata'), RNS serves as the best fit for a miscellaneous, non-financial, non-governance regulatory announcement.
2019-09-05 Italian
Parziale esercizio dell’opzione Greenshoe
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Shedir Pharma Group S.p.A. regarding the partial exercise of the Greenshoe option following their listing operation. The subject is 'Parziale esercizio dell'opzione Greenshoe' (Partial exercise of the Greenshoe option). This action directly relates to the capital structure and the shares allocated during the IPO process. Since it involves the issuance of new shares as part of a financing/capital event (the IPO stabilization mechanism), it falls under Capital/Financing Update (CAP). Although it mentions the capital increase, the core event reported is the finalization of the share allocation via the Greenshoe mechanism, which is a capital structure event. It is not a full report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital changes related to the listing. The document length is moderate (5367 chars), and it contains the full details, not just a pointer to an attachment, ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements.
2019-08-22 Italian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.